Published in BMJ on October 11, 2011
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med (2013) 2.60
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Dtsch Arztebl Int (2016) 1.77
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV (2015) 1.76
Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infect Dis Rep (2012) 1.53
Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention. PLoS Med (2015) 1.50
Recent HIV Testing Prevalence, Determinants, and Disparities Among U.S. Older Adult Respondents to the Behavioral Risk Factor Surveillance System. Sex Transm Dis (2015) 1.49
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
Association of Cardiometabolic Multimorbidity With Mortality. JAMA (2015) 1.32
Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis (2014) 1.25
Projected Lifetime Healthcare Costs Associated with HIV Infection. PLoS One (2015) 1.24
Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14
Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med (2013) 1.05
Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog (2014) 1.04
Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis (2015) 1.03
Poor uptake of primary healthcare registration among recent entrants to the UK: a retrospective cohort study. BMJ Open (2012) 1.01
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med (2015) 0.97
HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS (2013) 0.97
The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. PLoS One (2013) 0.96
Opt-out testing for blood-borne viruses in primary care: a multicentre, prospective study. Br J Gen Pract (2016) 0.96
Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study. J Int AIDS Soc (2013) 0.95
Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS (2016) 0.94
The cascade of care in the Eastern European country of Georgia. HIV Med (2014) 0.92
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. AIDS (2013) 0.92
Gender differences in baseline health, needs at release, and predictors of care engagement among HIV-positive clients leaving jail. AIDS Behav (2013) 0.90
Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles. PLoS One (2015) 0.87
Low levels of HIV test coverage in clinical settings in the U.K.: a systematic review of adherence to 2008 guidelines. Sex Transm Infect (2014) 0.87
Late HIV diagnosis is a major risk factor for intensive care unit admission in HIV-positive patients: a single centre observational cohort study. BMC Infect Dis (2013) 0.86
Assessing the predictive value of HIV indicator conditions in general practice: a case-control study using the THIN database. Br J Gen Pract (2013) 0.86
Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis (2016) 0.85
Feasibility and success of HIV point-of-care testing in an emergency department in an urban Canadian setting. Can J Infect Dis Med Microbiol (2013) 0.84
Unlocking the potential: longitudinal audit finds multifaceted education for general practice increases HIV testing and diagnosis. Sex Transm Infect (2012) 0.84
Chest computed tomography findings in HIV-infected individuals in the era of antiretroviral therapy. PLoS One (2014) 0.83
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS One (2015) 0.83
The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada. J Int AIDS Soc (2015) 0.82
Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes. AIDS Res Hum Retroviruses (2012) 0.82
HIV testing among clients in high HIV prevalence venues: disparities between older and younger adults. AIDS Care (2014) 0.82
Life expectancy in HIV. BMJ (2011) 0.80
Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. ISRN AIDS (2012) 0.80
'Waiting at the dinner table for scraps': a qualitative study of the help-seeking experiences of heterosexual men living with HIV infection. BMJ Open (2012) 0.79
Primary prophylaxis of disseminated histoplasmosis in HIV patients in French Guiana: arguments for cost effectiveness. Am J Trop Med Hyg (2013) 0.79
Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. J Int AIDS Soc (2015) 0.79
HIV and hepatitis C virus testing delays at methadone clinics in Guangdong Province, China. PLoS One (2013) 0.79
The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis. Ecancermedicalscience (2014) 0.77
TOGETHER Project to Increase Understanding of the HIV Epidemic Among Sub-Saharan African Migrants: Protocol of Community-Based Participatory Mixed-Method Studies. JMIR Res Protoc (2016) 0.77
Risk factors for early mortality after AIDS in the cART era: A population-based cohort study in Italy. BMC Infect Dis (2015) 0.77
Assessing the HIV rapid test in the fight against the HIV/AIDS epidemic in Trinidad. HIV AIDS (Auckl) (2013) 0.77
Expanded HIV Testing and Linkage to Care: Conventional vs. Point-of-Care Testing and Assignment of Patient Notification and Linkage to Care to an HIV Care Program. Public Health Rep (2016) 0.75
Republished: unlocking the potential: longitudinal audit finds multifaceted education for general practice increases HIV testing and diagnosis. Postgrad Med J (2014) 0.75
Personalized life expectancy and treatment benefit index of antiretroviral therapy. Theor Biol Med Model (2017) 0.75
HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. BMC Infect Dis (2016) 0.75
Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. HIV Med (2016) 0.75
Gaps in the Continuum of HIV Care: Long Pretreatment Waiting Time between HIV Diagnosis and Antiretroviral Therapy Initiation Leads to Poor Treatment Adherence and Outcomes. Biomed Res Int (2016) 0.75
Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations. PLoS One (2017) 0.75
Misdiagnosis of Treatable Stroke Mimic: The Case for HIV Screening in Practice Guidelines. Neurohospitalist (2013) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics. PLoS One (2016) 0.75
The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients. Open Forum Infect Dis (2015) 0.75
Trends in HIV infection in the First Affiliated Hospital of Harbin, China. BMC Infect Dis (2014) 0.75
Impact of Socioeconomic Inequality on Access, Adherence, and Outcomes of Antiretroviral Treatment Services for People Living with HIV/AIDS in Vietnam. PLoS One (2016) 0.75
Trends of and factors associated with live-birth and abortion rates among HIV-positive and HIV-negative women. Am J Obstet Gynecol (2016) 0.75
Life expectancy trends in adults on antiretroviral treatment in South Africa. AIDS (2016) 0.75
Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. Stat Med (2016) 0.75
Trends and level of control of hypertension among adults attending an ambulatory HIV clinic in Kampala, Uganda: a retrospective study. BMJ Glob Health (2016) 0.75
Effect of adiponectin-encoding gene ADIPOQ single nucleotide polymorphisms +45 and +276 on serum lipid levels after antiretroviral therapy in Japanese patients with HIV-1-infection. J Int Med Res (2016) 0.75
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Years of potential life lost (YPLL)--what does it measure? Epidemiology (1990) 3.23
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med (2004) 2.55
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS (2006) 2.42
Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr (2010) 2.21
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet (2003) 1.94
All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS (2004) 1.91
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS (2006) 1.71
Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS. J Gen Intern Med (2003) 1.56
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS (2007) 1.46
CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med (2007) 1.30
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med (2010) 1.23
Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr (2005) 1.17
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med (2008) 1.09
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (2008) 1.07
Stability of antiretroviral regimens in patients with viral suppression. AIDS (2008) 1.00
Life and death in the cART era. Lancet (2008) 0.98
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet (2014) 6.69
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS (2002) 5.67
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol (2011) 5.11
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect (2009) 3.92
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry (2002) 3.89
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos (2003) 3.33
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr (2010) 2.85
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Syphilis: old problem, new strategy. BMJ (2002) 2.73
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ (2012) 2.66
The gibberellin pathway mediates KNOTTED1-type homeobox function in plants with different body plans. Curr Biol (2002) 2.61
Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis (2013) 2.60
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
KNOX action in Arabidopsis is mediated by coordinate regulation of cytokinin and gibberellin activities. Curr Biol (2005) 2.54
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45